BUREAU-VERITAS
27.4.2020 21:40:05 CEST | Business Wire | Press release
Bureau Veritas , a world leader in testing, inspection and certification (TIC) services, has developed a suite of solutions to support companies of all sizes as they restart business activity.
Didier Michaud-Daniel, Chief Executive Officer, commented:
"The priority for all companies is to get back to work as quickly as possible and with appropriate health, safety and hygiene conditions for their employees and their clients. Building on 200 years of expertise in risk management, Bureau Veritas has developed a suite of solutions to meet the needs of all sectors of the economy as they reopen for business.
" Companies and public authorities with facilities open to the public need to demonstrate to their customers and users the implementation of the required protective measures. Companies in the industrial, construction and services sectors need to be able to protect their employees when they are back at work, whether on site or in their offices.
" Our geographical presence in 140 countries and unrivalled experience in certification processes is a considerable asset as it enables us to provide companies, public authorities and society as a whole with our services and our in-depth knowledge of local specificities and regulations.”
“Restart Your Business with BV” has been developed in collaboration with a range of experts and stakeholders. Bureau Veritas’ objectives are to:
- Ensure that health, safety and hygiene procedures put in place for the resumption of activity meet local and international regulations, as well as recognized best practices
- Confirm that the procedures defined are relevant to the specific needs of the company’s area of business, and that they are effectively implemented
- Deliver a certification or a conformity label thanks to its role of trustworthy independent third party.
“Restart Your Business with BV” is designed to address the risks specific to all places where people live and work from construction sites and factories to offices, hotels, restaurants, shops and public facilities.
“More than ever, our role as an expert, independent third party is crucial to creating the conditions for trust in this restart period,” adds Didier Michaud-Daniel. “Bureau Veritas is committed to deploy all efforts to protect the health and safety of your employees and customers.”
For more information on “Restart Your Business with BV”, please contact:
restartwithbv@bureauveritas.com
About Bureau Veritas
Bureau Veritas is a world-leading provider in testing, inspection and certification. Created in 1828, the Group has more than 78,000 employees located in more than 1,500 offices and laboratories around the globe. Bureau Veritas helps its clients to improve their performance by offering services and innovative solutions in order to ensure that their assets, products, infrastructure and processes meet standards and regulations in terms of quality, health and safety, environmental protection and social responsibility.
Bureau Veritas is listed on Euronext Paris and belongs to the Next 20 index.
Compartment A, ISIN code FR 0006174348, stock symbol: BVI.
For more information, visit www.bureauveritas.com
, and follow us on Twitter
(@bureauveritas) and LinkedIn
.
|
Our information is certified with blockchain technology.
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20200427005787/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth16.9.2026 14:01:00 CEST | Press release
AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trialsRubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind. This press release features multimedia. View
NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence16.9.2026 14:00:00 CEST | Press release
New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond. “NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infr
Unique Australian Clay: Multi Minerals Australia’s Non-antibiotic Solution for Poultry Production16.9.2026 13:44:00 CEST | Press release
Multi Minerals Australia, a leading mining company, announced a one-of-a-kind formulation of Australian clays which has proven it can reshape the global poultry feed economic landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916711777/en/ Unique, non-antibiotic clay stockfeed component and production enhancer from Multi Minerals Australia. Sourced from its one-of-a-kind geological deposit. Proven results. Worldwide distribution. Potential applications and lower cost benefits to a range of commercial animal production, particularly poultry. Expressions of interest sought. Numerous scientific, clinical, and commercial producer validations have demonstrated the product’s significant benefits; including the reduction of feed costs; improvements in: growth; meat yield; feed conversion; resistance to heat stress; eggshell quality and production: reduced inflammation and mortality in layer and broiler production. It has
Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 202616.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5A2utMmqiy/2vkuNBQpn65oayAPDgU4rZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treat
Bolstering its Executive Team, Taktile Welcomes Engineering Powerhouse James Broadhead as CTO16.9.2026 11:00:00 CEST | Press release
Broadhead to help propel Taktile’s global growth amid surging demand for AI-powered decisioning in banking and insurance Taktile, the leader in AI transformation for financial institutions, today announced it has hired engineering veteran James Broadhead as its chief technology officer. Broadhead, who is based in Dublin, Ireland, most recently worked at Databricks and brings nearly 15 years of experience in software engineering and development, including at X (Twitter), Neon and MongoDB. At Neon, Broadhead led engineering through exponential growth of the platform driven by Agentic software development, more than tripling company revenue before its acquisition by Databricks. “Taktile is growing rapidly across global markets, and James’ leadership will be instrumental as we expand our R&D function and global footprint,” said Taktile CEO and co-founder Maik Taro Wehmeyer. “James’ extensive background and expertise in engineering will take Taktile to the next level in powering mission-cri
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
